• Indications
  • Open Access TIMES Journals
Login Register
Login Register
Indications
  • Oncology · Hematology
  • Spine Surgery
  • Cardiovascular
  • Diabetes + Endocrinology
  • Pneumology
  • Ophthalmology
  • Gynecology · Urology
  • Dermatology · Immunology · Rheumatology
  • Neurology · Psychiatry
  • Gastroenterology
  • Infectiology · Anesthesiology · Pain
  • Primary Care
Open Access TIMES Journals
  • Oncology · Hematology
  • Spine Surgery
  • Cardiovascular
  • Diabetes + Endocrinology
  • Pneumology
  • Ophthalmology
  • Gynecology · Urology
  • Dermatology · Immunology · Rheumatology
  • Neurology · Psychiatry
  • Gastroenterology
  • Infectiology · Anesthesiology · Pain
  • Primary Care
Oncology · Hematology

Oncology · Hematology

Case Reports
Expert Opinions
Congress News
E-Learning
Webinar
Faculty
healthbook TIMES
Homepage >
Oncology · Hematology >
Articles

Advancing Breast Cancer Treatment with Elacestrant

Breast Cancer
Share:
Do you want to read an article? Please log in or register.
Register for Free
Remember me
Forgot password? Click here
SABCS 2024

Related content

SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Breast Cancer
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer
Ann Oncol
Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025
doi: 10.1016/j.annonc.2025.09.007
SPECIAL REPORT
Breast Cancer
Managing Side Effects in Breast Cancer Treatment
Breast Cancer
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer
Ann Oncol
Mamann A, Pradat Y, Bidard FC, Delaloge S, Cabel L, Faull I, Marques S, Bachelot T, Dalenc F, DE LA Motte Rouge T, Pistilli B, Samaniego J, Frenel JS, Levy C, Ferrero JM, Sabatier R, Ladoire S, Chakiba C, Hardy AC, Lemonnier J, Mahi Y, Andre F, Cournede PH, Michiels S, Bernard E
doi: 10.1016/j.annonc.2025.06.015
Breast Cancer
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study
Eur J Cancer
Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E
doi: 10.1016/j.ejca.2024.115219
SABCS 2025
Breast Cancer
DESTINY-Breast09: Favorable PROs with T-DXd plus pertuzumab in first-line HER2-positive advanced and metastatic breast cancer
SABCS 2025
Breast Cancer
CAPItello-291: ctDNA analyses confirm benefit of capivasertib plus fulvestrant in HR-positive advanced breast cancer
Breast Cancer
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-mutant Metastatic Breast Cancer
Clin Cancer Res
Rugo HS, Kaklamani V, McArthur H, Wander SA, Gradishar W, Mahtani R, Pegram M, Lustberg M, Swallow E, Maitland J, Kloss S, Wasserman T, Tolaney SM
doi: 10.1158/1078-0432.CCR-25-3040
Gastrointestinal Cancer
Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study
Int J Cancer
Slotman E, Pape M, van Laarhoven HWM, Pouw RE, van der Linden YM, Verhoeven RHA, Siesling S, Fransen HP, Raijmakers NJH
doi: 10.1002/ijc.35314
  • Contact us
  • About us
  • Privacy Policy & Disclaimer
  • Online Media 2025 Data
  • Imprint
healthbook is a registered trademark. Copyright © 2025 healthbook